Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting

Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

OBJECTIVES: This study sought to evaluate the role and incremental value of atropine in a large patient group undergoing dobutamine stress echocardiography. BACKGROUND: The use of atropine to potentiate dobutamine stress is not standard practice. Although the utility of atropine has been described, data on its incremental value remain limited and do not exist for a routine clinical practice setting. METHODS: Dobutamine stress echocardiography was performed in 1,171 patients with use of a standard protocol. Atropine (maximal dose 2.0 mg) was given to 299 patients (26%) who did not attain target heart rate. Coronary angiography was performed in 183 patients (46 received atropine), 148 of whom were found to have significant coronary artery disease (> or = 70% diameter stenosis in a major epicardial vessel, > or = 50% stenosis for left main coronary artery disease). All tests were reviewed independently by experienced observers. RESULTS: There were no major adverse events. Patients receiving atropine had a lower rest heart rate (65 vs. 74 beats/min, p < 0.0001) and more often received beta-adrenergic blocking agents (49% vs. 14%, p < 0.0001). Of 444 patients in whom stress-induced ischemia developed, 70 (16%) required atropine before ischemia became evident. Sensitivity for detection of significant coronary artery disease was 90% with dobutamine alone and 95% after the addition of atropine. In 66 patients with normal wall motion at rest, test sensitivity was 65% before and 84% after atropine was given. Atropine use did not compromise test specificity. New diagnostic information was obtained in 20 (50%) of 40 patients with angiographic coronary artery disease given atropine. Proportionately more patients with single-vessel disease required atropine before an ischemic response was observed; this effect appeared related to the higher ischemic threshold in these patients. CONCLUSIONS: Augmentation of heart rate had a modest influence on the overall diagnostic sensitivity of dobutamine stress echocardiography in our study cohort. However, it was particularly helpful in patients receiving beta-blockers and those with milder coronary disease. Despite the use of > or = 1 mg of atropine in some patients, this incremental value was not achieved at the expense of safety.

This article has been cited by other articles:

				R. Y. Kwong Imaging the Physiology of the Ischemic Cascade: Are 2 Tools Better Than 1? Circ Cardiovasc Imaging, September 1, 2008; 1(2): 92 - 93. [Full Text] [PDF]

				R. Sicari, P. Nihoyannopoulos, A. Evangelista, J. Kasprzak, P. Lancellotti, D. Poldermans, J.-U. Voigt, J. L. Zamorano, and on behalf of the European Association of Echocardi Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC) Eur J Echocardiogr, July 1, 2008; 9(4): 415 - 437. [Abstract] [Full Text] [PDF]

				A. Elhendy, E. L. O'Leary, F. Xie, A. C. McGrain, J. R. Anderson, and T. R. Porter Comparative accuracy of real-time myocardial contrast perfusion imaging and wall motion analysis during dobutamine stress echocardiography for the diagnosis of coronary artery disease J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2185 - 2191. [Abstract] [Full Text] [PDF]

				A. Wahl, I. Paetsch, S. Roethemeyer, C. Klein, E. Fleck, and E. Nagel High-Dose Dobutamine-Atropine Stress Cardiovascular MR Imaging after Coronary Revascularization in Patients with Wall Motion Abnormalities at Rest Radiology, October 1, 2004; 233(1): 210 - 216. [Abstract] [Full Text] [PDF]

				M. D. Cheitlin, W. F. Armstrong, G. P. Aurigemma, G. A. Beller, F. Z. Bierman, J. L. Davis, P. S. Douglas, D. P. Faxon, L. D. Gillam, T. R. Kimball, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography) J. Am. Coll. Cardiol., September 3, 2003; 42(5): 954 - 970. [Full Text] [PDF]

				M. D. Cheitlin, W. F. Armstrong, G. P. Aurigemma, G. A. Beller, F. Z. Bierman, J. L. Davis, P. S. Douglas, D. P. Faxon, L. D. Gillam, T. R. Kimball, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography) Circulation, September 2, 2003; 108(9): 1146 - 1162. [Full Text] [PDF]

				A D'Andrea, S Severino, P Caso, L De Simone, B Liccardo, A Forni, M Pascotto, G Di Salvo, M Scherillo, N Mininni, et al. Prognostic value of pharmacological stress echocardiography in diabetic patients Eur J Echocardiogr, September 1, 2003; 4(3): 202 - 208. [Abstract] [Full Text] [PDF]

				R. Hoffmann, T.H. Marwick, D. Poldermans, H. Lethen, R. Ciani, P. van der Meer, H.-P. Tries, P. Gianfagna, P. Fioretti, J.J. Bax, et al. Refinements in stress echocardiographic techniques improve inter-institutional agreement in interpretation of dobutamine stress echocardiograms Eur. Heart J., May 2, 2002; 23(10): 821 - 829. [Abstract] [Full Text] [PDF]

				E. Tadamura, H. Iida, K. Matsumoto, M. Mamede, S. Kubo, H. Toyoda, T. Shiozaki, T. Mukai, Y. Magata, and J. Konishi Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men J. Am. Coll. Cardiol., January 1, 2001; 37(1): 130 - 136. [Abstract] [Full Text] [PDF]

				S. Atar, T. Nagai, B. Cercek, T. Z. Naqvi, H. Luo, and R. J. Siegel Pacing stress echocardiography: an alternative to pharmacologic stress testing J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1935 - 1941. [Abstract] [Full Text] [PDF]

				M Sitges, C Pare, M Azqueta, X Bosch, M VelamazaN, J Magrina, and G Sanz Feasibility and prognostic value of dobutamine-atropine stress echocardiography early in unstable angina Eur. Heart J., July 1, 2000; 21(13): 1063 - 1071. [Abstract] [PDF]

				R. Hoffmann, H. Lethen, H. Kuhl, W. Lepper, and P. Hanrath Extent and severity of test positivity during dobutamine stress echocardiography. Influence on the predictive value for coronary artery disease Eur. Heart J., October 2, 1999; 20(20): 1485 - 1492. [Abstract] [PDF]

				W. A. Zoghbi and E. Barasch Dobutamine MRI: : A Serious Contender in Pharmacological Stress Imaging? Circulation, February 16, 1999; 99(6): 730 - 732. [Full Text] [PDF]

				E. Nagel, H. B. Lehmkuhl, W. Bocksch, C. Klein, U. Vogel, E. Frantz, A. Ellmer, S. Dreysse, and E. Fleck Noninvasive Diagnosis of Ischemia-Induced Wall Motion Abnormalities With the Use of High-Dose Dobutamine Stress MRI : Comparison With Dobutamine Stress Echocardiography Circulation, February 16, 1999; 99(6): 763 - 770. [Abstract] [Full Text] [PDF]

				S.-C. Chuah, P. A. Pellikka, V. L. Roger, R. B. McCully, and J. B. Seward Role of Dobutamine Stress Echocardiography in Predicting Outcome in 860 Patients With Known or Suspected Coronary Artery Disease Circulation, April 21, 1998; 97(15): 1474 - 1480. [Abstract] [Full Text] [PDF]

				M. L. Geleijnse, A. Elhendy, R. T. van Domburg, J. H. Cornel, R. Rambaldi, A. Salustri, A. E. M. Reijs, J. R. T. C. Roelandt, and P. M. Fioretti Cardiac Imaging for Risk Stratification With Dobutamine-Atropine Stress Testing in Patients With Chest Pain : Echocardiography, Perfusion Scintigraphy, or Both? Circulation, July 1, 1997; 96(1): 137 - 147. [Abstract] [Full Text]